You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Inexpensive, sensitive and specific, point-of-care diagnostic for bacterial infections in the central nervous system

    SBC: CNine Biosolutions            Topic: NIAID

    The objective of this Phase I application is to develop and assess a sMAC lateral flow assay diagnostic tool for bacterial meningitisBMDevelopment of rapidhighly sensitive and specific clinical diagnostic for bacterial infections in the central nervous systemCNSsuch as BM and shunt infectionthat are easy to use and cost effectivewould significantly improve healthcare in the US and worldwideWe have ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Neonatal hypoxia ischemiaHIremains a major cause of acute perinatal brain injuryleading ultimately to neurologic dysfunction manifesting as cerebral palsymental retardationand epilepsyUnfortunatelycurrent treatment and prevention strategies in newborns are limitedThere are no currently available therapies to prevent treat and or attenuate brain damage in premature infants other than supportive car ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia

    SBC: DISCOVERYBIOMED, INC.            Topic: 100

    DiscoveryBioMedIncDBMIncor DBMspecializes in normal and diseased human cell platform engineeringDBM has assembled a consortium of expertswherebycollectivelywe seek Fast Track SBIR funding to establish and offer a Product Line Menu of normal and ADPKD human cell platforms for the academic and industry marketplacesExisting and interested DBM clients will be presented in terms of which options in the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Developing Testing and Validating a Wearable Alcohol Biosensor

    SBC: Clinitech, LLC            Topic: 450

    PROJECT SUMMARY This application for a Phase I SBIR award represents a collaboration between Clinitech LLC and McLean Hospital Harvard Medical School to develop a wearable biosensor for detecting alcohol in the interstitial fluid of humans who have consumed alcohol Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Multi Scale In Vitro D Tissue Model of Vascularized Bone Cartilage Interactions

    SBC: CFD RESEARCH CORPORATION            Topic: NIAMS

    Abstract Current in vitro models of vascularized bone tissues do not mimic the in vivo microenvironment comprising of diverse cell types in communication with each other through stromal barriers In addition they are hampered by lack of real time visualization and quantitation of vasculature bone as well as bone cartilage interactions In contrast animal models while providing useful information ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Oral formulation for novel inhibitor of Ras driven cancers

    SBC: ADT Pharmaceuticals, LLC            Topic: NCI

    Mutations in the ras family of genes were first identified in human cancer overyears agoSuch mutations may result in the constitutive activation of one or more of three major Ras protein isoformsincluding H RasNRasor K Rasthat mediate important signaling pathways leading to uncontrolled cell growth and tumor developmentActivating mutations of ras genes occur de novo in approximately one third of a ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Evidence-Based Pain Intervention for Veterans: Leveraging Mobile and Social Media

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NCCIH

    Chronic musculoskeletal pain creates a significant public health burden, and Veterans are disproportionately affected. The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), all three conditions (Post-deployment Multi-symptom Disorder (PMD), and other multi-symptom syndromes can complicate and reduce the effectiveness of pain treatment. Furthermore, the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Endotoxin Neutralization as a Biomonitor for HIV Disease Progression

    SBC: BIODTECH, INC.            Topic: NIAID

    ABSTRACTEndotoxin neutralization in human plasma is an excellent indicator of chronic immune activationwhich is an accurate predictor of mortality in HIVinfectionRecently we developed an assay using endotoxin neutralization as an indicator of immune activation due to bacterial translocationThis assay is accurate in discriminating healthy patients from those with inflammatory bowel disease in addit ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Humanized Kidney Cellular Toxicity Platforms

    SBC: DISCOVERYBIOMED, INC.            Topic: NIEHS

    Principal Investigators for Small Business DiscoveryBioMed Inc DBM Project Summary Abstract The over arching goal of this proposed SBIR driven program is to create relevant DiscoveryBioMed DBM human cellular toxicity HCT platforms for the kidney grown in D and in D cell culture formats for a new gold standard in lead therapeutic asset and materials in vitro testing and to reduce marke ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government